Skip to main content
SpringerLink
Log in

Development and validation of a simple HPTLC method for the determination of new hepatitis C subtype 4 antiviral agents in their tablet dosage form

  • Original Research Paper
  • Published:
JPC – Journal of Planar Chromatography – Modern TLC Aims and scope Submit manuscript

Abstract

A new, simple, precise, accurate and selective high-performance thin-layer chromatographic (HPTLC) method has been developed and validated for the simultaneous determination of ledipasvir and sofosbuvir in their tablet dosage form. Chromatographic separation was carried out on Merck TLC aluminum sheets of silica gel 60 F254 using ethyl acetate:hexane:methanol in the ratio of 8:1.25:0.75 (% v/v) as the mobile phase followed by densitometric measurement at 256 nm. The method was validated in terms of linearity, accuracy, precision, limit of detection, limit of quantification and specificity in accordance with the International Conference on Harmonization (ICH) guidelines. The calibration curve was found to be linear between 60 to 1980 and 45 to 3600 ng/band for ledipasvir and sofosbuvir, respectively, with significantly high value of regression coefficient (r2 > 0.9999) with linear and homoscedastic residuals. The limits of detection and quantification were found to be 16.5 and 50 ng/band, respectively, for ledipasvir and 13 and 39.5 ng/band, respectively, for sofosbuvir. Comparative study was performed between the developed HPTLC method and the reported high-performance liquid chromatography (HPLC) method. The quantitative results of the two analytical methods did not show statistically significant difference, whereas the developed HPTLC method is both time- and cost-effective.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. WHO Secretariat (2010) Viral hepatitis. Sixty-Third World Health Assembly A63/15. Provisional agenda item 11.12. World Health Organization, Geneva, 2010

  2. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. J Sci 282:103–107

    CAS  Google Scholar 

  3. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P (2014) Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. J Hepatol 59:318–327

    Article  Google Scholar 

  4. Karoney MJ, Siika AM (2013) Hepatitis C virus (HCV) infection in Africa: a review. Pan Afr Med J 14:44

    PubMed  PubMed Central  Google Scholar 

  5. European Association for Study of Liver (2014) EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 60:392–420

    Article  Google Scholar 

  6. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pessôa MG, Lin A, Tietz A, Connell EV, Diago M (2010) A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139:1593–1601

    Article  CAS  Google Scholar 

  7. Pawlotsky JM (2013) NS5A inhibitors in the treatment of hepatitis C. Hepatology 59:375–382

    Article  CAS  Google Scholar 

  8. (2014) Sovaldi (sofosbuvir) prescribing information. Gilead Q5 319 Sciences, Inc., Foster City. https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf

  9. Sofia MJ (2014) Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C? Antivir Res 107:119–124

    Article  CAS  Google Scholar 

  10. Abergel A, Metivier S, Samuel D, Jiang D, Kersey K, Pang PS, Svarovskaia E, Knox SJ, Loustaud-Ratti V, Asselah T (2016) Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. J Hepatol 64:1049–1056

    Article  CAS  Google Scholar 

  11. Rezk MR, Basalious EB, Amin ME (2016) Novel and sensitive UPLC–MS/MS method for quantification of sofosbuvir in human plasma: application to a bioequivalence study. Biomed Chromatogr 30:1354–1362

    Article  CAS  Google Scholar 

  12. Rezk MR, Bendas ER, Basalious EB, Karim IA (2016) Development and validation of sensitive and rapid UPLC-MS/MS method for quantitative determination of daclatasvir in human plasma: application to a bioequivalence study. J Pharm Biomed Anal 128:61–66

    Article  CAS  Google Scholar 

  13. Rezk MR, Basalious EB, Karim IA (2015) Development of a sensitive UPLC-ESI-MS/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: application to a bioequivalence study. J Pharm Biomed Anal 114:97–104

    Article  CAS  Google Scholar 

  14. Shi X, Zhu D, Lou J, Zhu B, Hu AR, Gan D (2015) Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC–MS/MS. J Chromatogr B 1002:353–357

    Article  CAS  Google Scholar 

  15. Ranjana S, Nitin S, Ganesh T, Gholve SB (2016) Development and validation of simple UV spectrophotometric method for the determination of Ledipasvir in bulk form and stress degradation studies. Inventi Rapid: Pharm Analysis & Quality Assurance 3:1–5

  16. Devilal J, Durgaprasad B, Pal N, Rao AS (2016) New method development and validation for the determination of ledipasvir in bulk drug form by using reverse phase HPLC technique. World J Pharm Pharm Sci 8:1312–1321

  17. Nada SA, Nehal FF (2016) Innovative spectrophotometric methods for determination of newly discovered combination for hepatitis C treatment. J Anal Chem Lett 6:783–794

  18. Abdulkareem A, El-Tohamy MF (2017) Validated capillary zone electrophoresis approach for simultaneous separation and determination of hepatitis C Sofosbuvir and Ledipasvir in tablet dosage form. World J Pharm Res 6:129–147

  19. Hassouna MM, Abdelrahman MM, Mohamed MA (2017) Validation of a novel and sensitive RP-HPLC method for simultaneous determination of cefixime trihydrate and sodium benzoate in powder for oral suspension dosage form. J Forensic Sci 2:1–10

  20. Rezk MR, Bendas ER, Basalious EB, Karim IA (2016) Quantification of sofosbuvir and ledipasvir in human plasma by UPLC-MS/MS method: application to fasting and fed bioequivalence studies. J Chromatogr B 1028:63–70

  21. Ariaudo A, Favata F, De Nicolò A, Simiele M, Paglietti L, Boglione L, Cardellino CS, Carcieri C, Di Perri G, D'Avolio A (2016) A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma. J Pharm Biomed Anal 125:369–375

  22. Pan C, Chen Y, Chen W, Zhou G, Jin L, Zheng Y, Lin W, Pan Z (2016) Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. J Chromatogr B 1008:255–259

  23. Suganthi A, Satheshkumar S, Ravi TK (2019) Development of validated specific stability-indicating HPTLC method for the simultaneous determination of Ledipasvir and Sofosbuvir in fixed dose tablet formulation. Asian J Nanosci Mater 2:228–243

    Google Scholar 

  24. Saraya RE, Elhejnawee M, Saleh H (2018) Development of a highly sensitive high-performance thin-layer chromatography method for the screening and simultaneous determination of sofosbuvir, daclatasvir, and ledipasvir in their pure forms and their different pharmaceutical formulations. J Sep Sci 41:3553–3560

    Article  CAS  Google Scholar 

  25. ICH, Q2 (R1) Validation of analytical procedures: text and methodology, International Conference on Harmonization, IFPMA, Geneva, 2005

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta, Egypt

    Mahmoud M. Elkhoudary

  2. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sinai University, Arish, North Sinai, Egypt

    Mahmoud M. Elkhoudary & Basma M. Selim

  3. Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt

    Randa A. AbdelSalam, Ghada M. Hadad & Alaa El-Gindy

Authors
  1. Mahmoud M. Elkhoudary
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Basma M. Selim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Randa A. AbdelSalam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ghada M. Hadad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alaa El-Gindy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mahmoud M. Elkhoudary.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elkhoudary, M.M., Selim, B.M., AbdelSalam, R.A. et al. Development and validation of a simple HPTLC method for the determination of new hepatitis C subtype 4 antiviral agents in their tablet dosage form. JPC-J Planar Chromat 33, 71–77 (2020). https://doi.org/10.1007/s00764-019-00006-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00764-019-00006-y

Keywords

Search

Navigation